Table 2.
Characteristics of 34 920 waitlisted candidates in the United States from January 1, 2011, through December 31, 2013, by blood type
| Blood type
|
||||
|---|---|---|---|---|
| O n = 16 418 (47%) |
A n = 13 265 (38%) |
B n = 4134 (12%) |
AB n = 1103 (3%) |
|
| Age, years | 57 (50–62) | 56 (50–62) | 57 (49–62) | 57 (50–62) |
| Female | 40 | 41 | 39 | 39 |
| Race/ethnicity | ||||
| Non-Hispanic white | 67 | 77 | 62 | 68 |
| Hispanic white | 19 | 13 | 13 | 10 |
| Black | 9 | 6 | 14 | 10 |
| Asian | 4 | 3 | 10 | 11 |
| Other | 1 | 1 | 1 | 1 |
| Etiology of liver disease | ||||
| Alcohol | 19 | 19 | 17 | 17 |
| Chronic hepatitis C | 38 | 37 | 38 | 40 |
| Nonalcoholic fatty liver disease | 13 | 13 | 12 | 12 |
| Chronic hepatitis B | 3 | 3 | 5 | 5 |
| Autoimmune/cholestatic | 11 | 11 | 12 | 10 |
| Other | 16 | 17 | 16 | 16 |
| Hepatocellular carcinoma | 13 | 13 | 14 | 15 |
| Allocation MELD | ||||
| At listing | 14 (10–19) | 14 (10–19) | 14 (10–19) | 14 (10–19) |
| At transplant1 | 29 (23–36) | 28 (23–35) | 25 (22–33) | 23 (20–29) |
| Laboratory MELD | ||||
| At listing | 14 (10–19) | 14 (10–19) | 14 (10–19) | 13 (10–19) |
| At transplant1,2 | 27 (18–36) | 26 (18–35) | 24 (18–33) | 22 (16–31) |
| Albumin at listing, g/dL | 3.2 (2.7–3.6) | 3.2 (2.7–3.6) | 3.2 (2.7–3.7) | 3.2 (2.8–3.7) |
| Sodium at listing, mEq | 137 (134–140) | 137 (134–139) | 137 (134–140) | 137 (135–140) |
| Moderate ascites at listing | 26 | 27 | 25 | 25 |
| Encephalopathy at listing | 63 | 63 | 58 | 56 |
| Waitlist time, days | 380 (120–1024) | 365 (125–987) | 281 (96–913) | 196 (54–673) |
Data are shown as median (interquartile range) or percentage.
MELD, Model for End-Stage Liver Disease.
1
Among those who underwent liver transplant: n = 4665 for blood type O, n = 3835 for blood type A, n = 1456 for blood type B and n = 523 for blood type AB.
2
Among those without MELD exception points.